相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ipilimumab for the treatment of metastatic prostate cancer
Concetta Alaia et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis
Jianhong Zhu et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Targeted Therapies for the Treatment of Bone Metastases
Fable Zustovich et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Current treatment strategies for advanced prostate cancer
Kazumasa Komura et al.
INTERNATIONAL JOURNAL OF UROLOGY (2018)
Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise
Semini Sumanasuriya et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Sex steroids in the tumor microenvironment and prostate cancer progression
Clovis Boibessot et al.
ENDOCRINE-RELATED CANCER (2018)
Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)
Hendrik Borgmann et al.
EUROPEAN UROLOGY (2018)
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012
Maha Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617:Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer
S. Prekovic et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2018)
Revisiting the role of Wnt/β-catenin signaling in prostate cancer
Jeffrey A. Schneider et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2018)
The long tail of oncogenic drivers in prostate cancer
Joshua Armenia et al.
NATURE GENETICS (2018)
Clinical implications of PTEN loss in prostate cancer
Tamara Jamaspishvili et al.
NATURE REVIEWS UROLOGY (2018)
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
LSD1 activates a lethal prostate cancer gene network independently of its demethylase function
Archana Sehrawat et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Current approaches to incorporation of radium-223 in clinical practice
Chris Parker et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2018)
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
Matti Annala et al.
CANCER DISCOVERY (2018)
Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)
Yoon Ji Choi et al.
CANCER RESEARCH AND TREATMENT (2018)
Prostate cancer immunotherapy: where are we and where are we going?
Marco A. De Velasco et al.
CURRENT OPINION IN UROLOGY (2018)
A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone
L. Wang et al.
ANNALS OF ONCOLOGY (2018)
The molecular underpinnings of prostate cancer: impacts on management and pathology practice
Daniel Nava Rodrigues et al.
JOURNAL OF PATHOLOGY (2017)
Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075
Emily J. Faivre et al.
MOLECULAR CANCER RESEARCH (2017)
mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review
Cara M. Statz et al.
TARGETED ONCOLOGY (2017)
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
Cristina Saura et al.
CANCER DISCOVERY (2017)
Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors
Shu Feng et al.
ONCOTARGET (2017)
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
Christophe Massard et al.
EUROPEAN JOURNAL OF CANCER (2017)
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
Larysa H. M. Rydzewska et al.
EUROPEAN JOURNAL OF CANCER (2017)
Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response
Erik Bovinder Ylitalo et al.
EUROPEAN UROLOGY (2017)
BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations
Mark C. Markowski et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Darolutamide (ODM-201) for the treatment of prostate cancer
Neal D. Shore
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Advances toward LSD1 inhibitors for cancer therapy
Xiaoli Fu et al.
FUTURE MEDICINAL CHEMISTRY (2017)
Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer
Geoffrey Bryant et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Immunotherapy for Prostate Cancer: Where We Are Headed
Giuseppe Schepisi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Exploiting Epigenetic Alterations in Prostate Cancer
Simon J. Baumgart et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis
Matthew T. Jefferies et al.
JOURNAL OF PATHOLOGY (2017)
The importance of DNA methylation in prostate cancer development
Charles E. Massie et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2017)
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Samra Turajlic et al.
LANCET ONCOLOGY (2017)
Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions
Kush Dalal et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Loren M. Lasko et al.
NATURE (2017)
An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED
Wei Qi et al.
NATURE CHEMICAL BIOLOGY (2017)
TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer
Ken J. Kron et al.
NATURE GENETICS (2017)
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation
Pingzhao Zhang et al.
NATURE MEDICINE (2017)
Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors
Hana Janouskova et al.
NATURE MEDICINE (2017)
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication
Steven Lemery et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
DNA methylation and histone modifications as epigenetic regulation in prostate cancer (Review)
Maria Nowacka-Zawisza et al.
ONCOLOGY REPORTS (2017)
A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer
Grace A. Martin et al.
PHARMACOTHERAPY (2017)
A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study
Rahul Aggarwal et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2017)
Structure of the homodimeric androgen receptor ligand-binding domain
Marta Nadal et al.
NATURE COMMUNICATIONS (2017)
Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer
Miriam S. Butler et al.
ONCOTARGET (2017)
Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
Dominika E. Butler et al.
ONCOTARGET (2017)
Functional and therapeutic significance of EZH2 in urological cancers
Xiaobing Liu et al.
ONCOTARGET (2017)
Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials
Raphael B. Moreira et al.
ONCOTARGET (2017)
Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling
Styliani Karanika et al.
CELL REPORTS (2017)
Androgen Signaling in Prostate Cancer
Charles Dai et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases
Nicholas J. Vogelzang
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
Glucose Metabolism in the Progression of Prostate Cancer
Francesca Cutruzzola et al.
FRONTIERS IN PHYSIOLOGY (2017)
Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy
Shuang G. Zhao et al.
JAMA ONCOLOGY (2017)
Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
Luc Cabel et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
AR Signaling and the PI3K Pathway in Prostate Cancer
Megan Crumbaker et al.
CANCERS (2017)
Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model
Giacomo Canesin et al.
PLOS ONE (2017)
Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer
Dmitry S. Mikhaylenko et al.
CURRENT GENOMICS (2017)
SPOP-mediated degradation of BRD4 dictates cellular sensitivity to BET inhibitors
Xiangpeng Dai et al.
CELL CYCLE (2017)
Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer
Lingyan Jin et al.
CANCER RESEARCH (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature
Nicholas Summers et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression
Yi Liang et al.
CANCER RESEARCH (2017)
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Eric G. Bluemn et al.
CANCER CELL (2017)
Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer
Lesley J. Scott
DRUGS (2017)
Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol
Marie Lange et al.
BMC CANCER (2017)
Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges
Martin K. Bakht et al.
NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models
Mari I. Suominen et al.
CLINICAL CANCER RESEARCH (2017)
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone
Dana E. Rathkopf et al.
CLINICAL CANCER RESEARCH (2017)
ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor models
Antje Margret Wengner et al.
CANCER RESEARCH (2017)
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair
T. R. Shenoy et al.
ANNALS OF ONCOLOGY (2017)
Preclinical pharmacology of the PSMA-targeted thorium-227 conjugate PSMA-TTC: a novel targeted alpha therapeutic for the treatment of prostate cancer
Stefanie Hammer et al.
CANCER RESEARCH (2017)
PARP Inhibitors in Prostate Cancer
Praveen Ramakrishnan Geethakumari et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
A comprehensive review of immunotherapies in prostate cancer
Manuel Caitano Maia et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer
Xiaoju Wang et al.
CANCER CELL (2017)
Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer
Verena Zuber et al.
BMC GENOMICS (2017)
Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer
Matthew E. Pollard et al.
ASIAN JOURNAL OF UROLOGY (2017)
Prostate cancer, PI3K, PTEN and prognosis
Helen M. Wise et al.
CLINICAL SCIENCE (2017)
Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer
Zoran Culig
JOURNAL OF CELLULAR PHYSIOLOGY (2016)
The influence of subclonal resistance mutations on targeted cancer therapy
Michael W. Schmitt et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Addition of PSMA ADC to Enzalutamide Therapy Significantly Improves Survival in In Vivo Model of Castration Resistant Prostate Cancer
Vincent A. DiPippo et al.
PROSTATE (2016)
Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome
Sungyong You et al.
CANCER RESEARCH (2016)
Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity
Christine Pasero et al.
CANCER RESEARCH (2016)
Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer
Yu Chi Yang et al.
CLINICAL CANCER RESEARCH (2016)
Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness
Vijayalakshmi Kari et al.
EMBO REPORTS (2016)
Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification
David S. Priemer et al.
ENDOCRINE PATHOLOGY (2016)
Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence
Isabel Coutinho et al.
ENDOCRINE-RELATED CANCER (2016)
Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer
Edoardo Francini et al.
EUROPEAN UROLOGY (2016)
The Proteome of Primary Prostate Cancer
Diego Iglesias-Gato et al.
EUROPEAN UROLOGY (2016)
Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs
Kathy A. Gelato et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2016)
The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer
James M. Wilson et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer
Chiara Ciccarese et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
Drug discovery in advanced prostate cancer: translating biology into therapy
Timothy A. Yap et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer
Emmanuel S. Antonarakis et al.
ONCOLOGIST (2016)
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Kanak Raina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies
Ana Rita Lima et al.
TRANSLATIONAL ONCOLOGY (2016)
Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer
Marco A. De Velasco et al.
ONCOTARGET (2016)
Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigenspecific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation
Anthony S. Malamas et al.
ONCOTARGET (2016)
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
Kristine M. Wadosky et al.
ONCOTARGET (2016)
CYP17 inhibitors in prostate cancer: latest evidence and clinical potential
Anitha B. Alex et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials
Robert J. van Soest et al.
BMC MEDICINE (2015)
The genomic evolution of human prostate cancer
T. Mitchell et al.
BRITISH JOURNAL OF CANCER (2015)
Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
Sarit Schwartz et al.
CANCER CELL (2015)
Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
Peter F. Mulders et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse et al.
CELL (2015)
High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models
Rute B. Marques et al.
EUROPEAN UROLOGY (2015)
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
Karim Fizazi et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors
Yi-Chao Zheng et al.
MEDICINAL RESEARCH REVIEWS (2015)
Therapeutic cancer vaccine survives biotech bust
Heidi Ledford
NATURE (2015)
The evolutionary history of lethal metastatic prostate cancer
Gunes Gundem et al.
NATURE (2015)
Targeting the MLL complex in castration-resistant prostate cancer
Rohit Malik et al.
NATURE MEDICINE (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
NAR Breakthrough Article Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies
Siu Chiu Chan et al.
NUCLEIC ACIDS RESEARCH (2015)
Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure
Angela K. Green et al.
ONCOLOGIST (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations
Daan Joost De Maeseneer et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
Targeting BET bromodomains for cancer treatment
Marie Jung et al.
EPIGENOMICS (2015)
Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer
Changping Wu et al.
Oncotarget (2015)
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer
Jason S. Kirk et al.
ONCOTARGET (2015)
Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
Urs Hancox et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer
Sung Han Kim et al.
PLOS ONE (2015)
Synergistic Co-Targeting of Prostate-Specific Membrane Antigen and Androgen Receptor in Prostate Cancer
Jose D. Murga et al.
PROSTATE (2015)
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
Anu-Maarit Moilanen et al.
SCIENTIFIC REPORTS (2015)
Implications of Tumor Clonal Heterogeneity in the Era of Next-Generation Sequencing
Meagan A. Jacoby et al.
TRENDS IN CANCER (2015)
Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel
Ovidio Fernandez et al.
ANTI-CANCER DRUGS (2014)
Identification of a Potent Antiandrogen that Targets the BF3 Site of the Androgen Receptor and Inhibits Enzalutamide-Resistant Prostate Cancer
Ravi S. N. Munuganti et al.
CHEMISTRY & BIOLOGY (2014)
Radium Ra 223 Dichloride Injection: US Food and Drug Administration Drug Approval Summary
Paul G. Kluetz et al.
CLINICAL CANCER RESEARCH (2014)
Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies
Vincenza Conteduca et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
ETS fusion genes in prostate cancer
Delila Gasi Tandefelt et al.
ENDOCRINE-RELATED CANCER (2014)
Antibody-drug conjugates targeting prostate-specific membrane antigen
William C. Olson et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2014)
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Irfan A. Asangani et al.
NATURE (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Tumor clone dynamics in lethal prostate cancer
Suzanne Carreira et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Epigenetic modifications in prostate cancer
Marjolaine Ngollo et al.
EPIGENOMICS (2014)
Control of Embryonic Stem Cell Identity by BRD4-Dependent Transcriptional Elongation of Super-Enhancer-Associated Pluripotency Genes
Raffaella Di Micco et al.
CELL REPORTS (2014)
Punctuated Evolution of Prostate Cancer Genomes
Sylvan C. Baca et al.
CELL (2013)
Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth
Shivani Garapaty-Rao et al.
CHEMISTRY & BIOLOGY (2013)
Targeting Fibroblast Growth Factor Pathways in Prostate Cancer
Paul G. Corn et al.
CLINICAL CANCER RESEARCH (2013)
The Mutational Landscape of Prostate Cancer
Christopher E. Barbieri et al.
EUROPEAN UROLOGY (2013)
A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer
Christopher C. Parker et al.
EUROPEAN UROLOGY (2013)
Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity
Himisha Beltran et al.
EUROPEAN UROLOGY (2013)
Posttranslational Modification of the Androgen Receptor in Prostate Cancer
Travis van der Steen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Tracking the clonal origin of lethal prostate cancer
Michael C. Haffner et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Survival Benefit With Radium-223 Dichloride in a Mouse Model of Breast Cancer Bone Metastasis
Mari I. Suominen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
Anastasia Wyce et al.
ONCOTARGET (2013)
EZH2, an epigenetic driver of prostate cancer
Yeqing Angela Yang et al.
PROTEIN & CELL (2013)
Androgen Receptor on the Move: Boarding the Microtubule Expressway to the Nucleus
Maria Thadani-Mulero et al.
CANCER RESEARCH (2012)
Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors
Nicholas Mitsiades et al.
CANCER RESEARCH (2012)
Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer
Gary E. Gallick et al.
FUTURE MEDICINAL CHEMISTRY (2012)
Stepwise androgen receptor dimerization
Martin E. van Royen et al.
JOURNAL OF CELL SCIENCE (2012)
Androgen receptor-mediated gene repression
Andreas Grosse et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso et al.
NATURE (2012)
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Kexin Xu et al.
SCIENCE (2012)
Genome-wide DNA Methylation Events in TMPRSS2-ERG Fusion-Negative Prostate Cancers Implicate an EZH2-Dependent Mechanism with miR-26a Hypermethylation
Stefan T. Boerno et al.
CANCER DISCOVERY (2012)
Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
David J. Mulholland et al.
CANCER CELL (2011)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
Jeffrey J. Wallin et al.
MOLECULAR CANCER THERAPEUTICS (2011)
The genomic complexity of primary human prostate cancer
Michael F. Berger et al.
NATURE (2011)
Elevated Level of Wnt5a Protein in Localized Prostate Cancer Tissue Is Associated with Better Outcome
Azharuddin Sajid Syed Khaja et al.
PLOS ONE (2011)
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
Arkaitz Carracedo et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: A phase II California/Pittsburgh cancer consortium trial
Karen G. Chee et al.
CLINICAL GENITOURINARY CANCER (2007)
Post-translational modifications of steroid receptors
H. Faus et al.
BIOMEDICINE & PHARMACOTHERAPY (2006)
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
SA Tomlins et al.
SCIENCE (2005)
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription
E Metzger et al.
NATURE (2005)
Novel molecular aspects of prostate carcinogenesis
HA Meyer et al.
BIOMEDICINE & PHARMACOTHERAPY (2004)
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer
SY Wang et al.
CANCER CELL (2003)
The polycomb group protein EZH2 is involved in progression of prostate cancer
S Varambally et al.
NATURE (2002)
分享论文
